BioLizard CEO Liesbeth Ceelen among Trends’ 50 Belgians shaping the future

A well-deserved recognition for our CEO, Liesbeth Ceelen, has been named by Trends as one of the 50 Belgians expected to help shape the future over the next 50 years.

In an interview with journalist Benny Debruyne, Liesbeth shared her perspective on the challenges and opportunities of building and growing BioLizard in a rapidly changing world.

 

The world is evolving at an unprecedented pace, and staying ahead means continuously adapting, making strategic choices and embracing new opportunities. At BioLizard, this requires flexibility, vision, and the courage to keep moving forward, even when the right direction is not always immediately clear.

 

The interview also touches on a topic close to Liesbeth’s heart: entrepreneurship. She reflects on the importance of taking risks, continuing to invest and innovate, and creating an environment in which entrepreneurs receive the recognition and support they deserve.

 

Building a company is about much more than having a great idea. It takes perseverance, bold decisions and a willingness to keep learning and evolving.

 

We are delighted to see Liesbeth and the story behind BioLizard featured in Trends. This recognition reflects the ambition, dedication and entrepreneurial spirit that drive our company forward.

 

Read the full interview in Trends:

https://trends.knack.be/ondernemen/liesbeth-ceelen-ceo-van-biolizard-met-enkele-regels-code-alleen-kom-je-er-niet/

The Business of AI in Biotech: Why biotech is moving beyond the chatbox

The Business of AI in Biotech: Why biotech is moving beyond the chatbox

AI has quickly become part of everyday biotech research, helping scientists navigate information, write code and make sense of complex data. But chat-based tools have their limits. They can provide answers and guidance, but they cannot always do the actual scientific work. As biotech moves beyond the chatbox, the next step is putting AI to work directly within research workflows.